Immunotherapy
Description
The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist.
Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions.The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy.More details
Other editions
Additional editions
Previous edition
Persons
Dr. Aung Naing is a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.
Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Women in Clinical Immunology Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in inborn errors of immunity, microbiome in the immunocompromised host, and cancer immunotherapy.
Content
Table of contents
1. Immune System in Action
2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming
3. Immunotherapy for Melanoma
4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?
5. Landscape of Immunotherapy in Genitourinary Malignancies
6. Immuno-oncology for Gynecologic Malignancies
7. Immunotherapy for Neuro-oncology
8. Immunotherapy in Gastrointestinal Malignancies
9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!
10. CAR T-cells
11. Skin Reactions to Immune Checkpoint Inhibitors
12. Immunotherapy Mediated luminal Gastrointestinal toxicities
13. Hepatobiliary and Pancreatic Adverse Events
14. Pulmonary toxicities of immunotherapy
15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity
16. Renal Toxicity
17. Immune-Related Oral, Otologic and Ocular Adverse Events
18. Neurologic Toxicities of Immunotherapy
19. Cancer Imaging in Immunotherapy